MX344596B - Vacuna de subunidad recombinante del virus del dengue. - Google Patents
Vacuna de subunidad recombinante del virus del dengue.Info
- Publication number
- MX344596B MX344596B MX2013004741A MX2013004741A MX344596B MX 344596 B MX344596 B MX 344596B MX 2013004741 A MX2013004741 A MX 2013004741A MX 2013004741 A MX2013004741 A MX 2013004741A MX 344596 B MX344596 B MX 344596B
- Authority
- MX
- Mexico
- Prior art keywords
- dengue virus
- compositions
- den4
- present
- virus vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una composición inmunogénica, caracterizada porque comprende una cantidad eficaz de monómeros de la proteína de envoltura ("E") del virus del dengue purificados de serotipo DEN-1, DEN-2, DEN-3 y DEN-4, un excipiente farmacéuticamente aceptable, y una cantidad eficaz de adyuvante; en donde cada proteína E constituye aproximadamente el 80% de la longitud de la proteína E de tipo silvestre empezando desde el residuo de aminoácido 1 en su extremo N, de tal manera que dicha proteína E es secretable al medio de crecimiento cuando se expresa de manera recombinante en una célula hospedera; en donde la cantidad de la proteína E DEN4es aproximadamente de 1.5 a aproximadamente 3 veces las cantidades individuales de las proteínas E DEN1, DEN2 Y DEN3; y en donde la composición induce la producción de anticuerpos neutralizantes en sujetos humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40831010P | 2010-10-29 | 2010-10-29 | |
PCT/US2011/058026 WO2012154202A1 (en) | 2010-10-29 | 2011-10-27 | Recombinant subunit dengue virus vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013004741A MX2013004741A (es) | 2013-06-05 |
MX344596B true MX344596B (es) | 2016-12-20 |
Family
ID=47139466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013004741A MX344596B (es) | 2010-10-29 | 2011-10-27 | Vacuna de subunidad recombinante del virus del dengue. |
Country Status (10)
Country | Link |
---|---|
US (2) | US9198964B2 (es) |
EP (1) | EP2632485A4 (es) |
JP (1) | JP6018575B2 (es) |
KR (1) | KR20130138789A (es) |
AU (1) | AU2011367817B2 (es) |
BR (1) | BR112013009649A2 (es) |
MX (1) | MX344596B (es) |
MY (1) | MY166534A (es) |
SG (3) | SG10201801947YA (es) |
WO (1) | WO2012154202A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011119628A2 (en) | 2010-03-23 | 2011-09-29 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
EP2632485A4 (en) | 2010-10-29 | 2014-05-28 | Merck Sharp & Dohme | RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
MY187896A (en) | 2013-06-21 | 2021-10-27 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
GB201413086D0 (en) | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
MY192543A (en) | 2014-12-22 | 2022-08-26 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
WO2018217906A1 (en) * | 2017-05-23 | 2018-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus serotype 4 epitopes |
JP7042341B2 (ja) | 2017-12-07 | 2022-03-25 | メルク・シャープ・アンド・ドーム・コーポレーション | デングウイルスワクチン組成物の製剤 |
AU2018388102A1 (en) | 2017-12-21 | 2020-07-16 | Green Biomed, Inc. | Cross-immunizing antigen vaccine and method for preparation thereof |
CN112805030A (zh) * | 2018-08-14 | 2021-05-14 | 默沙东公司 | 利用成像细胞计数术的病毒中和测定法 |
KR102301130B1 (ko) * | 2018-12-27 | 2021-09-15 | 주식회사 이뮨메드 | 뎅기출혈열 진단 키트 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136561A (en) | 1995-05-24 | 2000-10-24 | Hawaii Biotechnology Group, Inc. | Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems |
ATE227584T1 (de) * | 1995-05-24 | 2002-11-15 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
KR20010022452A (ko) * | 1997-07-31 | 2001-03-15 | 추후제출 | 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신 |
US6416763B1 (en) | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
US6432411B1 (en) * | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
CU23245A1 (es) | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
AU2003300831A1 (en) | 2002-12-11 | 2004-06-30 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
BRPI0910476A2 (pt) | 2008-04-22 | 2018-03-27 | Cytios Biotechnology Ag | composições de vacinas para tratamento de febre do dengue e seus usos |
EP2632485A4 (en) | 2010-10-29 | 2014-05-28 | Merck Sharp & Dohme | RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS |
-
2011
- 2011-10-27 EP EP11865332.8A patent/EP2632485A4/en not_active Withdrawn
- 2011-10-27 KR KR1020137010730A patent/KR20130138789A/ko not_active Application Discontinuation
- 2011-10-27 JP JP2013536813A patent/JP6018575B2/ja not_active Expired - Fee Related
- 2011-10-27 SG SG10201801947YA patent/SG10201801947YA/en unknown
- 2011-10-27 WO PCT/US2011/058026 patent/WO2012154202A1/en active Application Filing
- 2011-10-27 BR BR112013009649A patent/BR112013009649A2/pt not_active Application Discontinuation
- 2011-10-27 MX MX2013004741A patent/MX344596B/es active IP Right Grant
- 2011-10-27 MY MYPI2013001004A patent/MY166534A/en unknown
- 2011-10-27 SG SG10201508700XA patent/SG10201508700XA/en unknown
- 2011-10-27 AU AU2011367817A patent/AU2011367817B2/en not_active Ceased
- 2011-10-27 SG SG2013021167A patent/SG189048A1/en unknown
- 2011-10-27 US US13/881,423 patent/US9198964B2/en active Active
-
2015
- 2015-09-22 US US14/861,425 patent/US10137187B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG10201801947YA (en) | 2018-04-27 |
JP6018575B2 (ja) | 2016-11-02 |
US20130216575A1 (en) | 2013-08-22 |
SG189048A1 (en) | 2013-05-31 |
EP2632485A4 (en) | 2014-05-28 |
MY166534A (en) | 2018-07-10 |
BR112013009649A2 (pt) | 2016-07-12 |
EP2632485A1 (en) | 2013-09-04 |
AU2011367817B2 (en) | 2015-05-28 |
SG10201508700XA (en) | 2015-11-27 |
MX2013004741A (es) | 2013-06-05 |
CN103179983A (zh) | 2013-06-26 |
KR20130138789A (ko) | 2013-12-19 |
US20160074502A1 (en) | 2016-03-17 |
US10137187B2 (en) | 2018-11-27 |
WO2012154202A1 (en) | 2012-11-15 |
US9198964B2 (en) | 2015-12-01 |
JP2013542224A (ja) | 2013-11-21 |
AU2011367817A1 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344596B (es) | Vacuna de subunidad recombinante del virus del dengue. | |
JP2013542224A5 (es) | ||
PL2643345T3 (pl) | Immunogenne peptydy do zastosowania w zapobieganiu i/lub leczeniu chorób zakaźnych, chorób autoimmunologicznych, odpowiedzi immunologicznych na czynniki allogeniczne, chorób alergicznych, nowotworów, odrzuceniu przeszczepów oraz odpowiedzi immunologicznych skierowanych przeciwko wektorom wirusowym stosowanym w terapii genowej lub szczepieniu genowym | |
PH12018502403A1 (en) | Hiv vaccine formulation | |
Egli et al. | Vaccine adjuvants–understanding molecular mechanisms to improve vaccines | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
JP2016508999A5 (es) | ||
RU2008114841A (ru) | Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса | |
IL182440A0 (en) | Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection | |
EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
Chen et al. | Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection | |
RU2013147745A (ru) | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей | |
PH12015502844B1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
Follador et al. | Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor | |
BR112013001946A2 (pt) | vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo | |
MX2022010781A (es) | Vacuna contra el virus sars-cov-2 con adyuvante cpg. | |
BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
WO2012073257A3 (en) | Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals | |
WO2010141084A3 (en) | Recombinant subunit west nile virus vaccine for protections of human subjects | |
AR097881A1 (es) | FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO | |
EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
IL208862A (en) | Use of a protein capable of eliciting an immune response against tat protein to prepare a drug for the prevention or treatment of AIDS (aids) in the patient and the preparations and vaccines associated with this use | |
PH12014502085B1 (en) | Modified marek`s disease virus, and vaccines made therefrom | |
Dávila et al. | Viral Control Induced by Therapeutic HIV Vaccine | |
TH142635A (th) | วัคซีนไวรัสไข้เลือดออกหน่วยย่อยรีคอมบิแนนท์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |